PRKAA1 and metabolic dysfunction-associated steatotic liver disease: Recently, Poxel announced the results of a phase 1b clinical trial for treatment of non-alcoholic fatty liver disease, indicating the potential for safe, therapeutic targeting of AMPK.45 AMPK phosphorylates at least 100 targets involved in regulating a number of diverse cellular pathways,46 and we lack a complete understanding of all of the effects of activating AMPK in vivo.